Egetis Therapeutics AB (ticker: -0ABW) reported a landmark third quarter for 2026, anchored by FDA approval of EMCITATE® (tiratricol) for treatment of peripheral thyrotoxicosis in patients with MCT8 deficiency — the first and only approved therapy for the condition in the United States. Following the quarter, the Swedish rare disease company agreed to sell a Rare Pediatric Disease Priority Review Voucher (PRV) for USD 190 million (approximately SEK 1,900 million), providing a substantial non-dilutive cash injection. Investors will be watching the pace of the U.S. commercial launch and the progression of tiratricol in a second rare thyroid indication, RTH-beta.

Key Points

  • Egetis Therapeutics AB (ticker: -0ABW), a Swedish rare disease company focused on rare thyroid hormone disorders
  • FDA approved EMCITATE® (tiratricol) on 28 September 2026 for MCT8 deficiency; U.S. commercial launch commenced 27 October 2026
  • Q3 2026 net revenue MSEK 21.5, up 24% at constant exchange rates; PRV sale agreed post-quarter for USD 190 million
  • Investors should watch U.S. patient uptake, European reimbursement outcomes, and RTH-beta development plan finalisation

FDA Approves EMCITATE® for MCT8 Deficiency and U.S. Launch Begins Ahead of Schedule

The FDA granted approval for EMCITATE on 28 September 2026, making it the first and only approved treatment for peripheral thyrotoxicosis in patients with MCT8 deficiency in the United States. MCT8 deficiency is a severe genetic disorder causing profound neurodevelopmental impairment and a median life expectancy of approximately 35 years. The U.S. commercial launch commenced on 27 October 2026, ahead of previously anticipated timelines. To support access, Egetis launched its RareLink™ patient support programme in partnership with PANTHERx® Rare, covering specialty distribution, care coordination, and ongoing treatment services for patients and healthcare professionals.

PRV Sale for USD 190 Million Strengthens Egetis Balance Sheet Post-Quarter

The FDA approval triggered the award of a Rare Pediatric Disease Priority Review Voucher, which Egetis and its subsidiary Rare Thyroid Therapeutics International AB (RTTI) agreed to sell on 4 November 2026 for USD 190 million, equivalent to approximately SEK 1,900 million. The announcement states that former owners of RTTI are entitled to approximately 50 percent of net proceeds as an earnout linked to Egetis's 2020 acquisition of EMCITATE. The company reported cash of MSEK 266.5 as of 30 September 2026, and describes the PRV proceeds as a significant non-dilutive contribution to financial flexibility as U.S. commercialisation accelerates.

Q3 Revenue Grows 24% at CER as Germany Leads European Sales

Egetis reported Q3 2026 net revenue of MSEK 21.5, a 24% increase at constant exchange rates compared with the same quarter in 2025. The quarterly result was MSEK -147.0, reflecting ongoing investment in commercialisation. For the nine months to September, net revenue reached MSEK 52.3, up 17% at CER. Germany remains the primary revenue market, being the first country where national reimbursement has been concluded with GKV-Spitzenverband. Reimbursement discussions are progressing in Spain, while Italy and France await publication of further EMCITATE survival data from Erasmus Medical Center before dossier advancement.

Tiratricol RTH-Beta Programme and International Expansion Add to Growth Pipeline

Beyond MCT8 deficiency, Egetis is advancing tiratricol as an investigational treatment for resistance to thyroid hormone beta (RTH-beta), a separate rare inherited disorder with no currently approved therapies. A retrospective study published in eBioMedicine, led by Erasmus Medical Center, reported statistically significant reductions in FT4 of 37% and TSH of 43% across 28 patients. Internationally, Egetis signed a collaboration and supply agreement with Orspec Pharma for Australia and New Zealand, while partner Fujimoto Pharmaceutical Corporation received Orphan Drug Designation for tiratricol in Japan. A Japanese NDA submission is expected in 2027, adding a further regulatory milestone for investors to monitor.